Overview

Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient

Status:
Completed

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

The primary aim of this study is to assess the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+Dipeptidyl peptidase 4 (DPP-4) inhibitors in poorly controlled type 2 diabetes mellitus (T2DM) patients. The study seeks to evaluate its effect on achieving glycemic goals in this patient population.

Phase:

Phase 4

Details

Lead Sponsor:

SINA Health Education and Welfare Trust

Collaborator:

Horizon Pharmaceutical Pvt Ltd

Treatments:

Dipeptidyl-Peptidase IV Inhibitors
Empagliflozin
Metformin